儿童和青少年脂质紊乱筛查:美国预防服务工作组更新证据报告和系统综述
该系统综述纳入43项研究(n=491516),未发现直接评价儿童脂质筛查获益与危害的随机对照试验。家族性高胆固醇血症(FH)表型患病率为0.2%至0.4%,他汀治疗可使FH儿童的总胆固醇和LDL-C较安慰剂额外降低81至82 mg/dL;多因素性血脂异常患病率较高,但行为咨询的短期效果未能持续。
要点
- 未发现直接评价儿童脂质筛查获益与危害的随机对照试验。
- FH表型患病率为0.2%至0.4%(1:250至1:500)。
- 他汀使FH儿童总胆固醇和LDL-C较安慰剂额外降低81至82 mg/dL。
核心结论
- 未发现直接评价儿童脂质筛查获益或危害的证据。
- 多因素性血脂异常常见,但未发现治疗对该情况有效的证据。
- FH相对罕见,证据表明他汀可降低FH儿童的血脂水平,观察性研究提示这种治疗对该病有长期获益。
研究设计与样本
- 系统综述纳入43项研究,总样本量n=491516。
- 检索MEDLINE和Cochrane对照试验中心注册库至2022年5月16日,文献监测至2023年3月24日。
- 纳入英文随机临床试验、报告诊断率或筛查阳性的近期大型美国队列研究以及降脂干预随机临床试验。
- 采用随机效应Meta分析进行定量合成。
主要发现
- 三项美国研究(n=395465)报告表型定义的FH患病率为0.2%至0.4%(1:250至1:500)。
- 五项研究(n=142257)报告多因素性血脂异常患病率:总胆固醇升高(≥200 mg/dL)为7.1%至9.4%,任何血脂异常为19.2%。
- 十项FH儿童和青少年随机临床试验(n=1230)显示,他汀在长达2年内使总胆固醇和LDL-C水平较安慰剂额外平均降低81至82 mg/dL。
- 非他汀药物试验显示FH人群血脂水平有统计学显著降低,但任何单一药物研究均较少。
- 观察性研究提示,从儿童或青少年期开始他汀治疗FH可降低长期心血管疾病风险。
关键数值与推荐
- FH表型患病率0.2%至0.4%(1:250至1:500)。
- 总胆固醇升高(≥200 mg/dL)患病率7.1%至9.4%,任何血脂异常患病率19.2%。
- 他汀治疗使总胆固醇和LDL-C较安慰剂额外平均降低81至82 mg/dL(长达2年)。
- 行为咨询使总胆固醇较对照组额外降低3至6 mg/dL,但最长随访未持续。
临床怎么用
- 原文未据此给出推荐。
局限性
- 未发现直接评价儿童脂质筛查获益与危害的随机对照试验。
- 非他汀药物试验中任何单一药物研究均较少。
- 行为咨询试验的发现未在最长随访时持续。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Lipid screening in childhood and adolescence can lead to early dyslipidemia diagnosis. The long-term benefits of lipid screening and subsequent treatment in this population are uncertain. OBJECTIVE: To review benefits and harms of screening and treatment of pediatric dyslipidemia due to familial hypercholesterolemia (FH) and multifactorial dyslipidemia. DATA SOURCES: MEDLINE and the Cochrane Central Register of Controlled Trials through May 16, 2022; literature surveillance through March 24, 2023. STUDY SELECTION: English-language randomized clinical trials (RCTs) of lipid screening; recent, large US cohort studies reporting diagnostic yield or screen positivity; and RCTs of lipid-lowering interventions. DATA EXTRACTION AND SYNTHESIS: Single extraction, verified by a second reviewer. Quantitative synthesis using random-effects meta-analysis. MAIN OUTCOMES AND MEASURES: Health outcomes, diagnostic yield, intermediate outcomes, behavioral outcomes, and harms. RESULTS: Forty-three studies were included (n = 491 516). No RCTs directly addressed screening effectiveness and harms. Three US studies (n = 395 465) reported prevalence of phenotypically defined FH of 0.2% to 0.4% (1:250 to 1:500). Five studies (n = 142 257) reported multifactorial dyslipidemia prevalence; the prevalence of elevated total cholesterol level (≥200 mg/dL) was 7.1% to 9.4% and of any lipid abnormality was 19.2%. Ten RCTs in children and adolescents with FH (n = 1230) demonstrated that statins were associated with an 81- to 82-mg/dL greater mean reduction in levels of total cholesterol and LDL-C compared with placebo at up to 2 years. Nonstatin-drug trials showed statistically significant lowering of lipid levels in FH populations, but few studies were available for any single drug. Observational studies suggest that statin treatment for FH starting in childhood or adolescence reduces long-term cardiovascular disease risk. Two multifactorial dyslipidemia behavioral counseling trials (n = 934) demonstrated 3- to 6-mg/dL greater reductions in total cholesterol levels compared with the control group, but findings did not persist at longest follow-up. Harms reported in the short-term drug trials were similar in the intervention and control groups. CONCLUSIONS AND RELEVANCE: No direct evidence on the benefits or harms of pediatric lipid screening was identified. While multifactorial dyslipidemia is common, no evidence was found that treatment is effective for this condition. In contrast, FH is relatively rare; evidence shows that statins reduce lipid levels in children with FH, and observational studies suggest that such treatment has long-term benefit for this condition.
引用
- Guirguis-Blake JM, Evans CV, Coppola EL, et al. Screening for Lipid Disorders in Children and Adolescents: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA. 2023. PMID: 37462700. doi:10.1001/jama.2023.8867
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。